晚期乳腺癌化疗后应用核糖核酸Ⅱ注射液的疗效及对外周血T细胞亚群的影响分析

Therapeutic effect of ribonucleic acid II injection after advanced breast cancer chemotherapy and the influence of peripheral blood T cell subsets

目的:探讨晚期乳腺癌新辅助化疗后应用核糖核酸Ⅱ注射液的疗效及对外周血T细胞亚群水平的影响。方法:回顾性分析2015年10月~2018年10月我院收治的80例晚期乳腺癌化疗患者的临床资料,将38例单纯采用常规化疗的作为对照组,将42例在化疗基础上联合核糖核酸Ⅱ注射液治疗的作为观察组。对比两组临床疗效、化疗前后免疫功能水平及外周血T细胞亚群水平。结果:观察组临床缓解率并不优于对照组,差异没有统计学意义(P>0.05);观察组化疗6个周期后IgA、IgG、IgM水平均高于对照组,差异有统计学意义(P<0.05);观察组化疗6个周期后CD4^+、CD8^+、CD69水平均高于对照组,差异有统计学意义(P<0.05)。结论:乳腺癌化疗后应用核糖核酸Ⅱ注射液并不能提高临床疗效,但是可以增强机体免疫能力,提高外周血T细胞亚群水平,从而达到降低副反应发生的目的,值得推广。

Objective:To investigate the effect of ribonucleic acid Ⅱ injection after advanced breast cancer chemotherapy and the influence of T cell subsets in peripheral blood.Methods:The clinical data of 80 patients with advanced breast cancer chemotherapy admitted to our hospital from October 2016 to October 2018 were retrospectively analyzed.38 patients who received conventional chemotherapy alone were used as control group,and 42 patients were combined with ribonucleic acid on the basis of chemotherapy.Patients treated with Ⅱ injection were used as observation groups.The clinical efficacy of the two groups,the level of immune function before and after chemotherapy,and the changes of peripheral blood T cell subsets were compared.Results:The clinical remission rate of the observation group was not better than that of the control group(P>0.05).The levels of IgA,IgG and IgM in the observation group were higher than those in the control group after 6 cycles of chemotherapy.The difference was statistically significant(P<0.05).The levels of CD4^+,CD8^+and CD69 in the observation group were higher than those in the control group after 6 cycles of chemotherapy(P<0.05).Conclusion:The application of ribonucleic acid Ⅱ injection after chemotherapy in breast cancer can not significantly improve the clinical efficacy,but enhance the immune system of patients and improve the level of T cell subsets in peripheral blood.It is worthy of promotion.